Literature DB >> 12477413

Inflexal V a trivalent virosome subunit influenza vaccine: production.

Robert Mischler1, Ian C Metcalfe.   

Abstract

Inflexal V, a novel virosome-based trivalent influenza vaccine, has been shown to be highly immunogenic and well tolerated in children, young adults, and the elderly. Here we discuss the techniques for the manufacture of Inflexal V, highlighting the purity and consistency of the manufacturing process. Key factors to be taken into account in the construction of Inflexal V are the retention of the natural presentation of antigens, its biodegradability and the presentation of few adverse events. The constituents of the vaccine were also carefully considered based on suitability for human use, adjuvanticity and an innate lack of toxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12477413     DOI: 10.1016/s0264-410x(02)00512-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  34 in total

Review 1.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

Review 2.  The role of nanotechnology in the treatment of viral infections.

Authors:  Lavanya Singh; Hendrik G Kruger; Glenn E M Maguire; Thavendran Govender; Raveen Parboosing
Journal:  Ther Adv Infect Dis       Date:  2017-07-05

Review 3.  Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines.

Authors:  Andrea Orsi; Filippo Ansaldi; Daniela de Florentiis; Antonella Ceravolo; Valentina Parodi; Paola Canepa; Martina Coppelli; Giancarlo Icardi; Paolo Durando
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

Review 4.  Protection of young children from influenza through universal vaccination.

Authors:  Nicola Principi; Laura Senatore; Susanna Esposito
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 5.  Developments in Vaccine Adjuvants.

Authors:  Farrhana Ziana Firdaus; Mariusz Skwarczynski; Istvan Toth
Journal:  Methods Mol Biol       Date:  2022

Review 6.  Immunobiology of influenza vaccines.

Authors:  Margarita M Gomez Lorenzo; Matthew J Fenton
Journal:  Chest       Date:  2013-02-01       Impact factor: 9.410

Review 7.  An update on the prevention of influenza in children and adolescents.

Authors:  Ulrich Heininger
Journal:  Eur J Pediatr       Date:  2003-10-21       Impact factor: 3.183

8.  Clonal dissection of the human memory B-cell repertoire following infection and vaccination.

Authors:  Debora Pinna; Davide Corti; David Jarrossay; Federica Sallusto; Antonio Lanzavecchia
Journal:  Eur J Immunol       Date:  2009-05       Impact factor: 5.532

Review 9.  Micro and Nano Material Carriers for Immunomodulation.

Authors:  E Bracho-Sanchez; C Q Xia; M J Clare-Salzler; B G Keselowsky
Journal:  Am J Transplant       Date:  2016-06-27       Impact factor: 8.086

10.  Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.

Authors:  Zachary R Sia; Matthew S Miller; Jonathan F Lovell
Journal:  Mol Pharm       Date:  2020-08-17       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.